Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Jarrod Longcor, Kate Oliver, BS

Blood (2019) 134 (Supplement_1): 1864.

https://doi.org/10.1182/blood-2019-131806

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

https://doi.org/10.1182/blood-2019-131014

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Blood (2019) 134 (Supplement_1): 5328.

https://doi.org/10.1182/blood-2019-122635

Published: 2019

Journal Articles

The First 100 Cases of Epstein-Barr Virus-Positive Mucocutaneous Ulcers

Ryan B. Sinit, David M. Aboulafia, MD, Russell K. Dorer, MD PhD

Blood (2018) 132 (Supplement 1): 5340.

https://doi.org/10.1182/blood-2018-99-110278

Published: 2018

Journal Articles

Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Remco J Molenaar, MDPhD, Tomas Radivoyevitch, Aaron T. Gerds, MDMS, Aziz Nazha, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2018) 132 (Supplement 1): 900.

https://doi.org/10.1182/blood-2018-99-118207

Published: 2018

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Michele Maharaj, RN, OCN, CCRP, Katherine Oliver, BS, CCRP, Natalie Scott Callander, MD

Blood (2016) 128 (22): 4485.

https://doi.org/10.1182/blood.V128.22.4485.4485

Published: 2016

Journal Articles

Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes

Christopher Pleyer, MD, Surbhi Sidana, MD, Tomas Radivoyevitch, PhD, Remco Molenaar, MD, Andrew Godley, PhD, Erik Offerman, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD

Blood (2015) 126 (23): 612.

https://doi.org/10.1182/blood.V126.23.612.612

Published: 2015

Journal Articles

Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study

Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Pamela R Soulos, MPH, James B. Yu, MD, Amy J. Davidoff, PhD, Steven D. Gore, MD, Cary P. Gross, MD, Xiaomei Ma, PhD

Blood (2015) 126 (23): 3295.

https://doi.org/10.1182/blood.V126.23.3295.3295

Published: 2015

Journal Articles

Risk Of Acute and Chronic Leukemias Following Radiation Treatment For Locoregional Prostate Cancer In The United States Over 35-Years

Sudipto Mukherjee, MD, PhD, MPH, Chandana A. Reddy, Jay P. Ciezki, MD, Ramon V. Tiu, MD, Anjali S. Advani, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Brian J. Bolwell, MD, Matt Kalaycio, MD, Eric A. Klein, MD, Mikkael A. Sekeres, MD, MS

Blood (2013) 122 (21): 2652.

https://doi.org/10.1182/blood.V122.21.2652.2652

Published: 2013

Journal Articles

Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation

Michael Humeniuk, M.D., Morie A. Gertz, M.D., Martha Q. Lacy, MD, Robert A. Kyle, MD, Suzanne R. Hayman, MD, Shaji K. Kumar, MD, John A. Lust, MD, PhD, Thomas E. Witzig, MD, Francis K. Buadi, M.D., S. Vincent Rajkumar, MD, Steven R. Zeldenrust, MD, PhD, Stephen J. Russell, MD, PhD, David Dingli, M.D., Ph.D., Yi Lin, MD, Prashant Kapoor, MD, Nelson Leung, MD, Angela Dispenzieri, MD

Blood (2012) 120 (21): 448.

https://doi.org/10.1182/blood.V120.21.448.448

Published: 2012

Journal Articles

Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Adam J. Olszewski, MD, Amrita Desai, MD, MPH

Blood (2012) 120 (21): 2053.

https://doi.org/10.1182/blood.V120.21.2053.2053

Published: 2012

Journal Articles

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Thomas E. Witzig, MD, Fangxin Hong, Ph.D., Ivana N. Micallef, MD, Randy D. Gascoyne, MD, Ahmet Dogan, MD, PhD, Henry Wagner, Jr., MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 2687.

https://doi.org/10.1182/blood.V120.21.2687.2687

Published: 2012

Journal Articles

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

Brian L. Burnette, MD, Gregory Wiseman, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD, PhD, Luis F. Porrata, MD, David James Inwards, MD, Patrick B. Johnston, Ivana Micallef, William R Macon, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski

Blood (2011) 118 (21): 1640.

https://doi.org/10.1182/blood.V118.21.1640.1640

Published: 2011

Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD

Blood (2011) 118 (21): 1648.

https://doi.org/10.1182/blood.V118.21.1648.1648

Published: 2011

Journal Articles

Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation

Sarah C. Rutherford, MD, Wayne Tam, MD, PhD, Richard R. Furman, MD, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Morton Coleman, MD, John P. Leonard, MD, Peter Martin, MD

Blood (2011) 118 (21): 1579.

https://doi.org/10.1182/blood.V118.21.1579.1579

Published: 2011

Journal Articles

Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)

Sudipto Mukherjee, Chandana Reddy, Jay Ciezki, Ramon V. Tiu, MD, Edward A. Copelan, MD, Anjali S. Advani, MD, Yogen Saunthararajah, MD, Katarina Paulic, Jaroslaw P. Maciejewski, MD, PhD, Brian J. Bolwell, Eric A. Klein, MD, Mikkael A. Sekeres, MD, MS

Blood (2011) 118 (21): 120.

https://doi.org/10.1182/blood.V118.21.120.120

Published: 2011

Journal Articles

A Comparative Investigation of Therapeutic Approaches for Primary Prostate Cancer and Risk of Acute Myeloid Leukemia.

Rohit P. Ojha, MPH, Raymond Thertulien, MD, PhD, Deepak Prabhakar, MD, MPH, Yi Zhou, MS, Lori A. Fischbach, PhD, MPH

Blood (2007) 110 (11): 1816.

https://doi.org/10.1182/blood.V110.11.1816.1816

Published: 2007

Journal Articles

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

Bita Esmaeli, MD, Barbara Pro, MD, M. Wayne Saville, MD, Peter McLaughlin, MD

Blood (2005) 106 (11): 4792.

https://doi.org/10.1182/blood.V106.11.4792.4792

Published: 2005

NARROW

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

The First 100 Cases of Epstein-Barr Virus-Positive Mucocutaneous Ulcers

Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes

Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study

Risk Of Acute and Chronic Leukemias Following Radiation Treatment For Locoregional Prostate Cancer In The United States Over 35-Years

Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation

Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation

Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)

A Comparative Investigation of Therapeutic Approaches for Primary Prostate Cancer and Risk of Acute Myeloid Leukemia.

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only